HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, J. Articles by Dugi, K. A. Search for Related Content PubMed PubMed Citation Articles by Schneider, J. Articles by Dugi, K. A. Social Bookmarking                What's this?

The Proline 12 Alanine Substitution in the Peroxisome Proliferator–Activated Receptor-2 Gene Is Associated With Lower Lipoprotein Lipase Activity in Vivo

¹ Department of Internal Medicine I (Endocrinology, Diabetes and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany
² Department of Internal Medicine III (Cardiology), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany

Lipoprotein lipase (LPL) plays a key role in lipid metabolism by hydrolyzing triglycerides in circulating lipoproteins. Low LPL activity has been linked to coronary artery disease (CAD), but the factors influencing LPL expression are not completely understood. Peroxisome proliferator–activated receptor (PPAR)- is a nuclear receptor regulating lipid and glucose metabolism, and a PPAR-responsive element is present in the LPL promoter. We determined the Pro12Ala polymorphism in the PPAR-2 gene in 194 male CAD patients because this allele is associated with decreased PPAR activity and reduced LPL promoter activity in vitro. Presence of 12Ala was associated with 20% lower LPL activity in postheparin plasma (141 ± 58 vs. 177 ± 77 nmol · ml^-1 · min^-1, P < 0.005). Remarkably, the influence of 12Ala on LPL was greater than that of the frequent polymorphisms (HindIII +9%, PvuII ±0%, 447stop +12%) in the LPL gene itself. To confirm these results in a different group of patients, we analyzed 100 diabetic patients in whom the 12Ala allele was also associated with lower LPL activity (12Ala: 132 ± 88 vs. 190 ± 129 nmol · ml^-1 · min^-1, P < 0.05). Our data demonstrate that the Pro12Ala substitution in PPAR-2 is associated with lower LPL activity in vivo and provides a new target for the analysis of genetic influences on LPL activity and CAD risk.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. Knouff and J. Auwerx Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology Endocr. Rev., December 1, 2004; 25(6): 899 - 918. [Abstract] [Full Text] [PDF]

				S Masud and S Ye Effect of the peroxisome proliferator activated receptor-{gamma} gene Pro12Ala variant on body mass index: a meta-analysis J. Med. Genet., October 1, 2003; 40(10): 773 - 780. [Full Text] [PDF]

				M. Kolehmainen, M. I. J. Uusitupa, E. Alhava, M. Laakso, and H. Vidal Effect of the Pro12Ala Polymorphism in the Peroxisome Proliferator-Activated Receptor (PPAR) {gamma}2 Gene on the Expression of PPAR{gamma} Target Genes in Adipose Tissue of Massively Obese Subjects J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1717 - 1722. [Abstract] [Full Text] [PDF]